english.prescrire.org > Spotlight > Archives : 2016 > In the December issue of Prescrire International: Cobimetinib (Cotellic°) and metastatic melanoma

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2016 : 1 | 30 | 60

In the December issue of Prescrire International: Cobimetinib (Cotellic°) and metastatic melanoma

FREE DOWNLOAD Clinical evaluation of cobimetinib in patients with metastatic or inoperable melanoma positive for the BRAF V600 mutation confirms that frontline treatment with a MEK kinase inhibitor plus a BRAF inhibitor prolongs survival by a few months, at a cost of many potentially serious adverse effects.
Full text available for free download.

Summary

  • Cobimetinib (Cotellic°, Roche) is another MEK kinase inhibitor. It is solely authorised in the European Union for use in combination with vemurafenib.
     
  • In mid-2016, there seems to be no noteworthy clinical difference between the harm-benefit balance of the cobimetinib + vemurafenib combination and the trametinib + dabrafenib combination.
     
  • However, the trametinib + dabrafenib combination is better evaluated and carries a lower risk of drug interactions.
     

Full text available for free download.

 ©Prescrire 1 December 2016

"Cobimetinib (Cotellic°) and metastatic melanoma" Prescrire Int 2016; 25 (177): pp. (Pdf, free)
Download the full review
Pdf, free

See also:

Metastasised or non-operable
melanomas: progress
(December 2016)
Free